Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is February 25, 2026, covering share purchases executed on February 24, 2026. The transaction was conducted through BNP Paribas SA as part of GSK's existing share buyback programme under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for this transaction include:
- Shares Purchased: 477,000 ordinary shares.
- Price Range: Lowest price paid was 2,175.00 GBp; highest price paid was 2,217.00 GBp.
- Average Price: Volume-weighted average price paid was 2,200.50 GBp.
- Treasury Holdings: Following this purchase, GSK holds 242,597,094 ordinary shares in treasury.
- Shares in Issue: 4,073,555,332 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.96% of total voting rights.
The filing text does not provide values for revenue, profit, cash flow, margins, or debt levels.
Material Changes
Since the announcement of the non-discretionary agreement on February 17, 2026, GSK has purchased a total of 2,706,000 ordinary shares. The specific purchase reported in this filing increased the company's treasury share count and reduced the number of shares in issue. No other material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no specific guidance or outlook regarding future financial performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q4 Results for 2025. The purchased shares are to be held as Treasury shares.
Investor Verification Checklist
- Verify the total cumulative buyback volume since February 17, 2026 (stated as 2,706,000 shares).
- Confirm the updated treasury share count of 242,597,094 and the resulting 5.96% voting rights attribution.
- Review the referenced Annual Report on Form 20-F for 2024 and Q4 2025 results for detailed risk factors and broader financial context not included in this transaction report.
- Check the specific trading venues (BATE, CHIX, XLON) for execution details if analyzing market impact.